PENGARUH PEMBERIAN EICOSAPENTAENOIC ACID ( EPA ) TERHADAP JUMLAH SEL T CD4 PADA PASIEN KARSINOMA MAMAE STADIUM III YANG MENDAPATKAN KEMOTERAPI

Abstract

Backgrounds: Breast cancer patients in general are acquiring cellular immune system depression. Chemotherapy admitted to those patients is also playing role in their immune depression. Eicosapentaenoic Acid (EPA) is an essential fatty acid which may increase cellular immune system activity. Purpose: To Proves there any improvement of number of T cells CD4 at group of bosom cancer patient experiencing chemotherapy with giving of EPA compared to without giving EPA. Methods: This Randomized Control Group Pre and Post Test Design included 40 patients of breast cancer ductus invasive stadium IIIb. They were divided into 2 groups, first receiving chemotherapy and EPA, while second receiving chemotherapy only. CD4 cell count was measured in both groups before and after 20 days of therapy. Descriptive analysis and association study were performed with SPSS 15.0. Results: Mann Whitney test results showed no significant difference of CD4 cell count post therapy between second (579,5 ± 228,0) and first group (701,7 ± 418,5) with p value 0,495. Differences of CD4 cell count between first (-70,7 ± 765,7) and second group (-79,6 ± 205,62) were also insignificant.Wilcoxon test showed insignificant differences in first group between pre (772,4 ± 679,9) and post therapy (701,7 ± 418,5) with p value 0,495. Conclusion : Number of T cells CD4 breast cancer patient getting chemotherapy CAF and higher EPA compared to which is not got EPA, although signifikan doesn't statistically. Group that is is not gets EPA to experience degradation of number of bigger CD4 T cells compared to with getting EPA. Keywords: Eicosapentaenoic Acid, CD 4 cell count, breast cancer ductus invasive stadium III, chemotherapy.